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Increase in Renal Transplantation of Sensitized Recipients Following the 
Introduction of Virtual Crossmatching: One Center’s Experience
Abstract:
Michael J Moritz, MD1, Lynsey A Biondi, MD1, Patricia Kimble, BS2 and Robert Cirocco, PhD2  
Single Antigen Bead (SAB) technology provides more accurate identification of 
anti-HLA antibodies. Thus the Virtual (predicted) Crossmatch (XM) should be 
more accurate. We implemented both in 2009 while abandoning a limit on the 
number of HLA mismatches. We followed transplantation of sensitized patients 
(cPRA>50%), biopsy proven rejection (BPAR) and the number of deceased 
donor (DD) XM’s. Sensitized patients transplanted rose from 9% (11 of 124, 
2007-2008) to 20% (37 of 187, 2009-2011). The mean cPRA in the earlier group 
was 57% and was 85% in the latter. The rejection incidence did not change 
despite the higher degree of sensitization transplanted. Conclusions: 1) The 
Virtual XM enabled an increase in the number of renal transplants in sensitized 
recipients; 2) The degree of sensitization for this group has risen. 3) The rejection 
rate has not risen in sensitized recipients. 4) Post transplant IVIG prophylaxis 
























2006 3 68 3% 99% NA NA NA
2007 5 54 9% 57% 18.0 214 NA
2008 6 70 9% 75% 18.9 228 202
2009 15 75 20% 80% 21.6 263 188
2010 11 65 17% 85% 18.1 316 152
2011 11 57 19% 86% 18.0 335 132
Introduction:
Sensitive XM’s led to an increasing pool of high PRA, sensitized patients. 
Between 2002 to 2008, PRA>20% increased from 17% to 21% of the national 
wait list. For new registrants, PRA>20% increased from 10% to 18%. The 
poor success rate (~50%) in predicting compatible XM’s in sensitized patients 
delayed allocation and led us to mandate a degree of matching for highly 
sensitized patients.
Methods:
In 2009, our HLA laboratory adopted SAB. Flow XM technique remained 
standard. This study observed the numbers of DD XM’s, transplants performed, 
and patients’ PRA to determine the impact of SAB. Post transplant, ACR (acute 
cellular rejection), AMR (antibody mediated rejection), and graft loss were 
followed.
All kidney only transplants from 2006 through 2011 were included. All transplants 
were XM compatible; no desensitization. Standard immunosuppression for 
all was rATG induction (4-6mg/kg in 3-4 doses), methylprednisolone on days 
0 and 1 followed by steroid-free 2 drug maintenance with tacrolimus and 
mycophenolate. Protocol biopsies were at 1, 6, and 12 months. Biopsy proven 
acute rejection (BPAR) was defined as ACR in the first year post transplant, and 
includes subclinical rejection (i.e. protocol biopsy) and clinical rejection. Highly 
sensitized was defined as current PRA>50%.
Results:
For the following time periods, the % of transplants in highly sensitized 
patients was: 2006, 4%; 2007-08, 9%; and 2009-11, 20%. As the number of 
sensitized patients transplanted rose, mean cPRA and BPAR did not change. 
The ratio of subclinical to clinical rejection did not change at 1:1.
The incidence of AMR rose. In 2006, 1of 3 highly sensitized recipients had 
early graft loss from AMR. In 2007-08, 11 highly sensitized recipients had 4 
AMR’s with 1 graft loss. Between 2009-2/2010, 16 recipients had 6 AMR’s, 
with 2 graft losses. IVIG prophylaxis was initiated in 3/2010 for recipients 
with PRA>80% (adapted from Ref. 2). The next 21 have had 2 AMR episodes, 
neither with graft loss.
Patient and graft survival in the highly sensitized (n=51) has been similar to the 
non-sensitized. Graft survival at 1 year is 44 of 51 (86%). Patient survival at 1 
year is 50 of 51 (98%). Our last SRTR report showed overall 1 year graft and 
patient survival of 92% and 98%.
Discussion:
SAB dramatically improves anti-HLA antibody definition. It was hoped that this 
would result in more accurate Virtual XM, predicting compatible final XM’s, 
despite very sensitive flow XM’s. The data support better Virtual XM with a 
higher transplant rate and fewer XM’s (Ref. 1).
The number of kidney transplants to highly sensitized recipients has risen, and 
approximates their proportion of candidates, restoring equilibrium. This has 
been accomplished with fewer XM’s, increasing laboratory efficiency. We have 
seen no decrement in outcome compared to non-sensitized recipients. IVIG 
prophylaxis against AMR appears to be effective.
Priority for the highly sensitized has been difficult to balance for 2 major 
reasons. One, the greater the priority, the more final XM’s to be performed. 
Two, sensitization was associated with poorer outcomes. Lack of enthusiasm 
for these transplants led to center-based obstacles such as mandating a level 
of matching. Our data show that these center-based hurdles are no longer 
necessary, either for logistic (reason #1) or outcome (reason #2) rationales. Final 
XM’s have a ~95% agreement with Virtual XM, and recipient outcomes (with 
steroid-free immunosuppression and AMR prophylaxis) appear not different 
from non-sensitized recipients.
Conclusions:
1  Virtual XM’ing enabled an increase in the number of renal transplants in 
sensitized recipients.
2  The degree of sensitization transplanted has risen. 
3  The rejection rate has not risen in sensitized recipients. 





DD XM’s Total number of candidates XM’ed, NA not available









ACR (in the 
first year)
+DSA (in the 
first year)
# and Causes of 
Graft Loss (in the 
first Year)
2006 None 3 2 1 0 NA 1:AMR
2007-2008 None 11 4 1 0 4 2:	1	AMR,
1:	Coag	










Coag.-coagulopathy with biopsy complication; NC-non-compliance; CHF-congestive heart failure; TMA-thrombotic microangiopathy
